Expectations

Every patient, in fact
every member of the methadone community, has a right to expect that
someone who represents themselves as a methadone advocate be knowledgeable
in all aspects of methadone treatment.


NAMA has created the Methadone Advocate Training and
Methadone Advocate Certification for a whole host of reasons. Most of
which we will discuss in Washington, DC at the first CMA Training..
However, the most obvious is:

To give persons interested in doing methadone advocacy work the best
possible set of tools to accomplish the goals of Methadone Advocacy.

 


CONTINUE

Similar Posts

  • Announcement of Approval of OTP Accrediting Organizations

    Admin 04/21/2021

    Center for Substance Abuse Treatment December 4, 2001 Dear Opioid Treatment Program Sponsor: This letter is to apprize you of significant developments affecting opioid treatment programs. On November 30, the Substance Abuse and Mental Health Services Administration (SAMHSA) announced the approval of four accreditation bodies (enclosed) under the new opioid treatment program regulations (42 CFR…

  • Invitational Conference on Drug User Activism

    Admin 02/11/2023

    International Drug User Day 2003, October 31st/November 1st Copenhagen, Denmark Early Morning Smiles Eliot Albert (Methadone Alliance on loan to BF) finishes up some work in preparation for his workshop. Final Check Eliot Albert (Methadone Alliance) takes a final walk through the kitchen and reception area to make sure every is ready for the arrival…

  • Next Training

    Admin 01/14/2022

    Training Schedule Certified MAT Advocate Training at the AATOD 2021 Conference . When: Saturday, April 10, 2021 Starts: 9 AM Where: The AATOD Conference will be virtual (Webinar) Register and Pay (Note: Regisration and Payment is through the Georgia Board.) Go Here Download Materials Training Materials For information about the conference visit the AATOD Conference…

  • Category: AATOD

    Admin 12/26/2021

    Congratulations to Sara Gefvert, the 2022 Lane/Holden Award Winner! November 2, 2022 The 2022 Richard Lane/Robert Holden Patient Advocacy Award was presented at an Awards Reception held in conjunction with the 2022 Conference of the American Association for the Treatment of Opioid Dependence (AATOD) in Baltimore, Maryland on November 2, 2022. Richard Lane/Robert Holden Patient…

  • Answer one

    Admin 12/31/2022

    FALSE! Current research shows that doses below 60 mg/day are “not effective and hence not appropriate” and that low dose policies for pregnant and non-pregnant patients are associated with increased drug use as well as reduced program retention. Medical withdrawal of opioid dependent women is not recommended in pregnancy because of increased risk to the…